PriceTargets.com logo

Sage Therapeutics - SAGE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.53
  • Forecasted Upside: 105.52%
  • Number of Analysts: 20
  • Breakdown:
  • 2 Sell Ratings
  • 16 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.61 As of 12/20/2024 06:16 PM ET
▲ +0.61 (12.20%)

This chart shows the closing price for SAGE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sage Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAGE

Analyst Price Target is $11.53
▲ +105.52% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Sage Therapeutics in the last 3 months. The average price target is $11.53, with a high forecast of $26.00 and a low forecast of $4.00. The average price target represents a 105.52% upside from the last price of $5.61.

This chart shows the closing price for SAGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 20 polled investment analysts is to hold stock in Sage Therapeutics. This rating has held steady since October 2024, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 17 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 16 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 15 hold ratings
  • 2 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 16 hold ratings
  • 2 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 17 hold ratings
  • 2 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 16 hold ratings
  • 2 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 16 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/16/2024Stifel NicolausLower TargetHold ➝ Hold$10.00 ➝ $6.00
11/21/2024TD CowenLower TargetHold ➝ Hold$10.00 ➝ $9.00
11/21/2024Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$4.00 ➝ $4.00
11/20/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$14.00 ➝ $14.00
11/20/2024Needham & Company LLCReiterated RatingHold
10/30/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$17.00 ➝ $14.00
10/30/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$52.00 ➝ $26.00
10/30/2024OppenheimerLower TargetMarket Perform ➝ Market Perform$9.00 ➝ $8.00
10/30/2024Truist FinancialLower TargetHold ➝ Hold$13.00 ➝ $8.00
10/30/2024HC WainwrightLower TargetNeutral ➝ Neutral$25.00 ➝ $14.00
10/30/2024Needham & Company LLCReiterated RatingHold
10/17/2024Needham & Company LLCReiterated RatingHold
10/10/2024Raymond JamesReiterated RatingMarket Perform
10/9/2024Bank of AmericaLower TargetUnderperform ➝ Underperform$11.00 ➝ $6.00
10/9/2024WedbushLower TargetNeutral ➝ Neutral$9.00 ➝ $8.00
10/9/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
10/9/2024Robert W. BairdLower TargetNeutral ➝ Neutral$13.00 ➝ $9.00
10/8/2024Needham & Company LLCReiterated RatingHold
10/4/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$10.00 ➝ $4.00
8/14/2024Truist FinancialLower TargetHold ➝ Hold$18.00 ➝ $13.00
8/6/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$12.00 ➝ $10.00
8/2/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
8/1/2024Needham & Company LLCReiterated RatingHold
7/30/2024TD CowenDowngradeBuy ➝ Hold$16.00 ➝ $10.00
7/26/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$19.00 ➝ $11.00
7/25/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$19.00 ➝ $17.00
7/25/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
7/25/2024Robert W. BairdLower TargetNeutral ➝ Neutral$15.00 ➝ $13.00
7/25/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $12.00
7/24/2024Needham & Company LLCReiterated RatingHold
7/19/2024MizuhoLower TargetNeutral ➝ Neutral$18.00 ➝ $16.00
7/12/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$23.00 ➝ $18.00
7/2/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
6/28/2024Needham & Company LLCReiterated RatingHold
6/20/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$28.00 ➝ $23.00
6/12/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
6/11/2024Robert W. BairdReiterated RatingNeutral ➝ Neutral$15.00 ➝ $15.00
6/11/2024Needham & Company LLCReiterated RatingHold
5/29/2024Baird R WUpgradeHold
5/29/2024Robert W. BairdInitiated CoverageNeutral$15.00
5/29/2024CitigroupInitiated CoverageSell$8.00
5/1/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$29.00 ➝ $28.00
4/26/2024HC WainwrightLower TargetNeutral ➝ Neutral$28.00 ➝ $25.00
4/26/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$28.00 ➝ $19.00
4/26/2024Truist FinancialLower TargetHold ➝ Hold$22.00 ➝ $18.00
4/26/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$26.00 ➝ $15.00
4/26/2024MizuhoLower TargetNeutral ➝ Neutral$20.00 ➝ $18.00
4/26/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$21.00 ➝ $17.00
4/25/2024Needham & Company LLCReiterated RatingHold
4/18/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$34.00 ➝ $19.00
4/18/2024OppenheimerLower TargetMarket Perform ➝ Market Perform$25.00 ➝ $17.00
4/18/2024Needham & Company LLCReiterated RatingHold
4/18/2024TD CowenLower TargetBuy ➝ Buy$30.00 ➝ $16.00
4/17/2024WedbushReiterated RatingNeutral ➝ Neutral$24.00
4/17/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$28.00
4/17/2024Bank of AmericaDowngradeNeutral ➝ Underperform$24.00 ➝ $14.00
3/26/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$24.00 ➝ $29.00
2/28/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$20.00 ➝ $22.00
2/15/2024HC WainwrightBoost TargetNeutral ➝ Neutral$25.00 ➝ $28.00
2/15/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$21.00 ➝ $26.00
12/18/2023Stifel NicolausLower TargetHold ➝ Hold$22.00 ➝ $20.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$21.00
11/8/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$22.00 ➝ $21.00
11/8/2023WedbushBoost TargetNeutral ➝ Neutral$21.00 ➝ $22.00
10/13/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$22.00 ➝ $25.00
9/8/2023Bank of AmericaLower TargetNeutral ➝ Neutral$25.00 ➝ $24.00
9/7/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$25.00 ➝ $22.00
9/7/2023MizuhoBoost TargetNeutral ➝ Neutral$19.00 ➝ $20.00
9/1/2023ScotiabankBoost Target$24.00 ➝ $27.00
8/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$49.00 ➝ $20.00
8/8/2023TD CowenLower TargetOutperform ➝ Outperform$105.00 ➝ $28.00
8/8/2023OppenheimerLower TargetMarket Perform ➝ Market Perform$24.00 ➝ $20.00
8/8/2023Truist FinancialLower TargetHold ➝ Hold$40.00 ➝ $20.00
8/8/2023MizuhoLower TargetNeutral ➝ Neutral$45.00 ➝ $19.00
8/8/2023HC WainwrightLower Target$50.00 ➝ $27.00
8/8/2023The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$75.00 ➝ $22.00
8/8/2023Needham & Company LLCDowngradeBuy ➝ Hold
8/8/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$64.00 ➝ $21.00
8/8/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$64.00 ➝ $21.00
8/7/2023BarclaysLower Target$311.00 ➝ $294.00
8/7/2023Bank of AmericaDowngradeBuy ➝ Neutral$66.00 ➝ $25.00
8/7/2023Stifel NicolausDowngradeBuy ➝ Hold$60.00 ➝ $22.00
8/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$70.00
8/7/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$50.00
8/7/2023WedbushDowngradeOutperform ➝ Neutral$51.00 ➝ $22.00
8/7/2023OppenheimerDowngradeOutperform ➝ Market Perform
8/7/2023Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$71.00 ➝ $25.00
8/3/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$49.00
7/27/2023ScotiabankInitiated CoverageOutperform
6/15/2023Bank of AmericaBoost Target$61.00 ➝ $66.00
5/23/2023Bank of AmericaBoost Target$56.00 ➝ $61.00
5/3/2023VNET GroupReiterated RatingMaintains
5/3/2023Royal Bank of CanadaBoost Target$60.00 ➝ $63.00
3/13/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$40.00 ➝ $60.00
3/9/2023HC WainwrightReiterated RatingNeutral$50.00
2/17/2023HC WainwrightReiterated RatingNeutral$50.00
2/17/2023Needham & Company LLCReiterated RatingBuy$70.00
2/17/2023CitigroupBoost TargetNeutral$40.00 ➝ $46.00
2/17/2023MizuhoBoost TargetNeutral$37.00 ➝ $45.00
1/3/2023GuggenheimDowngradeBuy ➝ Neutral
12/6/2022JPMorgan Chase & Co.Lower TargetOverweight$92.00 ➝ $60.00
11/21/2022Morgan StanleyLower TargetEqual Weight$53.00 ➝ $50.00
11/11/2022GuggenheimLower TargetBuy$55.00 ➝ $48.00
11/9/2022BMO Capital MarketsLower TargetMarket Perform$43.00 ➝ $40.00
11/9/2022HC WainwrightLower TargetNeutral$55.00 ➝ $50.00
11/1/2022Loop CapitalInitiated CoverageHold$41.00
8/3/2022CitigroupLower Target$41.00 ➝ $40.00
8/2/2022Stifel NicolausLower Target$58.00 ➝ $56.00
7/11/2022Leerink PartnersLower TargetMarket Perform$50.00 ➝ $40.00
6/3/2022CitigroupBoost Target$41.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$85.00 ➝ $73.00
5/4/2022MizuhoLower Target$41.00 ➝ $37.00
3/31/2022Berenberg BankInitiated CoverageHold$37.00
3/10/2022Morgan StanleyLower TargetEqual Weight$61.00 ➝ $57.00
3/9/2022Truist FinancialLower TargetHold$60.00 ➝ $40.00
3/3/2022MizuhoLower TargetNeutral$44.00 ➝ $41.00
2/25/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$95.00 ➝ $64.00
2/25/2022Leerink PartnersLower TargetMarket Perform$60.00 ➝ $50.00
2/17/2022The Goldman Sachs GroupLower TargetBuy$96.00
1/6/2022Needham & Company LLCBoost TargetBuy$79.00 ➝ $85.00
12/20/2021Leerink PartnersLower TargetMarket Perform$70.00 ➝ $60.00
11/18/2021Needham & Company LLCReiterated RatingBuy$78.00
11/18/2021MizuhoLower TargetNeutral$52.00 ➝ $44.00
11/3/2021OppenheimerLower TargetOutperform$84.00 ➝ $80.00
11/3/2021HC WainwrightLower TargetNeutral$80.00 ➝ $55.00
11/2/2021Royal Bank of CanadaLower TargetSector Perform$52.00 ➝ $48.00
11/2/2021GuggenheimUpgradeNeutral ➝ Buy$55.00
10/20/2021Needham & Company LLCInitiated CoverageBuy$84.00 ➝ $80.00
10/20/2021OppenheimerLower TargetPositive ➝ Outperform$100.00 ➝ $84.00
10/18/2021Leerink PartnersReiterated RatingMarket Perform
10/12/2021Morgan StanleyLower TargetEqual Weight$81.00 ➝ $78.00
10/7/2021Leerink PartnersReiterated RatingHold
10/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$100.00 ➝ $50.00
10/4/2021Stifel NicolausLower TargetBuy$95.00 ➝ $75.00
9/22/2021Needham & Company LLCInitiated CoverageBuy$84.00
8/4/2021Royal Bank of CanadaLower TargetSector Perform$60.00 ➝ $55.00
8/4/2021HC WainwrightLower TargetNeutral$86.00 ➝ $80.00
6/16/2021Leerink PartnersLower TargetMarket Perform$90.00 ➝ $70.00
6/16/2021HC WainwrightReiterated RatingHold
6/16/2021Stifel NicolausLower TargetBuy$121.00 ➝ $95.00
6/16/2021William BlairDowngradeOutperform ➝ Market Perform$62.00
6/16/2021BMO Capital MarketsLower TargetPositive ➝ Market Perform$87.00 ➝ $73.00
6/16/2021CitigroupDowngradeBuy ➝ Neutral$101.00 ➝ $68.00
5/5/2021MizuhoLower TargetNeutral$81.00 ➝ $77.00
4/19/2021Morgan StanleyLower TargetEqual Weight$87.00 ➝ $81.00
4/12/2021MizuhoReiterated RatingHold$81.00
4/7/2021Piper SandlerInitiated CoverageOverweight$100.00
3/4/2021MizuhoReiterated RatingBuy ➝ Neutral$81.00
3/2/2021Morgan StanleyBoost TargetEqual Weight$83.00 ➝ $87.00
2/26/2021MizuhoDowngradeBuy ➝ Neutral$81.00
2/25/2021OppenheimerBoost TargetOutperform$90.00 ➝ $102.00
2/25/2021HC WainwrightBoost TargetNeutral$74.00 ➝ $86.00
2/25/2021HC WainwrightReiterated RatingNeutral$74.00 ➝ $86.00
2/1/2021Raymond JamesInitiated CoverageMarket Perform
1/22/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$95.00
1/19/2021WedbushBoost TargetOutperform$83.00 ➝ $98.00
1/4/2021GuggenheimUpgradeNeutral ➝ Buy
1/4/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$83.00 ➝ $86.00
12/4/2020William BlairReiterated RatingBuy
12/4/2020MizuhoUpgradeNeutral ➝ Buy$77.00 ➝ $81.00
12/1/2020Truist FinancialBoost Target$60.00 ➝ $70.00
12/1/2020Smith Barney CitigroupLower Target$100.00 ➝ $93.00
12/1/2020Royal Bank of CanadaLower Target$86.00 ➝ $83.00
12/1/2020HC WainwrightLower TargetNeutral$81.00 ➝ $74.00
12/1/2020Morgan StanleyLower TargetEqual Weight$85.00 ➝ $83.00
11/30/2020Raymond JamesDowngradeOutperform ➝ Market Perform
11/19/2020OppenheimerBoost Target$65.00 ➝ $94.00
11/16/2020Bank of AmericaBoost TargetBuy$72.00 ➝ $95.00
11/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$87.00 ➝ $85.00
11/10/2020Truist FinancialBoost TargetHold$35.00 ➝ $60.00
11/6/2020Smith Barney CitigroupBoost Target$67.00 ➝ $100.00
11/6/2020MizuhoBoost TargetNeutral$53.00 ➝ $77.00
11/6/2020BMO Capital MarketsBoost TargetOutperform$79.00 ➝ $89.00
11/6/2020HC WainwrightBoost TargetNeutral$76.00 ➝ $81.00
10/20/2020Royal Bank of CanadaBoost TargetOutperform$75.00 ➝ $84.00
10/16/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$65.00 ➝ $79.00
9/11/2020CitigroupBoost TargetPositive ➝ Buy$54.00 ➝ $67.00
9/11/2020WedbushUpgradeNeutral ➝ Outperform$40.00 ➝ $65.00
8/24/2020Morgan StanleyBoost TargetOverweight$85.00 ➝ $87.00
8/11/2020Royal Bank of CanadaReiterated RatingBuy
8/11/2020OppenheimerBoost TargetOutperform$50.00 ➝ $65.00
8/10/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$70.00
8/10/2020MizuhoReiterated RatingHold$44.00
5/26/2020Royal Bank of CanadaBoost TargetOutperform$72.00 ➝ $75.00
5/8/2020SunTrust BanksLower TargetHold$37.00 ➝ $35.00
5/8/2020Royal Bank of CanadaBoost TargetOutperform$71.00 ➝ $72.00
5/8/2020WedbushDowngradeOutperform ➝ Neutral$36.00 ➝ $37.00
5/8/2020MizuhoBoost TargetNeutral$36.00 ➝ $44.00
4/28/2020Royal Bank of CanadaBoost TargetOutperform$68.00 ➝ $71.00
4/19/2020GuggenheimDowngradeBuy ➝ Neutral
4/9/2020BMO Capital MarketsLower TargetOutperform$86.00 ➝ $65.00
4/9/2020SunTrust BanksLower TargetHold$40.00 ➝ $37.00
4/8/2020Royal Bank of CanadaBoost TargetOutperform$60.00 ➝ $68.00
4/8/2020WedbushLower TargetOutperform$56.00 ➝ $36.00
4/8/2020OppenheimerLower TargetOutperform$60.00 ➝ $50.00
4/8/2020CitigroupBoost TargetBuy$48.00 ➝ $54.00
4/8/2020GuggenheimDowngradeBuy ➝ Neutral
4/8/2020MizuhoLower TargetNeutral$58.00 ➝ $36.00
3/26/2020SunTrust BanksLower TargetHold$50.00 ➝ $40.00
3/22/2020HC WainwrightReiterated RatingHold$78.00
3/20/2020LADENBURG THALM/SH SHReiterated RatingHold$28.00
3/19/2020OppenheimerLower Target$97.00 ➝ $60.00
3/19/2020Leerink PartnersBoost TargetMarket Perform$45.00 ➝ $63.00
3/19/2020GuggenheimLower TargetBuy$85.00 ➝ $65.00
3/19/2020CitigroupLower TargetBuy$71.00 ➝ $48.00
3/18/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$73.00 ➝ $60.00
3/11/2020MizuhoReiterated RatingHold$58.00
3/5/2020CitigroupInitiated CoverageBuy$71.00
3/3/2020Morgan StanleyLower TargetOverweight$125.00 ➝ $117.00
2/28/2020SunTrust BanksLower TargetHold$60.00 ➝ $50.00
2/28/2020LADENBURG THALM/SH SHReiterated RatingHold$52.00
2/28/2020HC WainwrightLower TargetNeutral$87.00 ➝ $78.00
2/28/2020MizuhoLower TargetNeutral$69.00 ➝ $58.00
2/27/2020CowenReiterated RatingBuy$96.00
2/27/2020MizuhoReiterated RatingHold$69.00
2/5/2020MizuhoInitiated CoverageNeutral$69.00
1/7/2020Bank of AmericaBoost Target$85.00 ➝ $98.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 10 very positive mentions
  • 35 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 62 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 9 very positive mentions
  • 83 positive mentions
  • 11 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 8 very positive mentions
  • 34 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Sage Therapeutics logo
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.61
Low: $4.95
High: $5.62

50 Day Range

MA: $6.07
Low: $4.78
High: $8.54

52 Week Range

Now: $5.61
Low: $4.62
High: $28.26

Volume

4,336,741 shs

Average Volume

984,327 shs

Market Capitalization

$343.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?

The following sell-side analysts have issued reports on Sage Therapeutics in the last year: Baird R W, Bank of America Co., Canaccord Genuity Group Inc., Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., and Wedbush.
View the latest analyst ratings for SAGE.

What is the current price target for Sage Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Sage Therapeutics in the last year. Their average twelve-month price target is $11.53, suggesting a possible upside of 105.5%. Piper Sandler has the highest price target set, predicting SAGE will reach $26.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $4.00 for Sage Therapeutics in the next year.
View the latest price targets for SAGE.

What is the current consensus analyst rating for Sage Therapeutics?

Sage Therapeutics currently has 2 sell ratings, 16 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SAGE, but not buy more shares or sell existing shares.
View the latest ratings for SAGE.

What other companies compete with Sage Therapeutics?

Other companies that are similar to Sage Therapeutics include Ardelyx, Spyre Therapeutics, Calliditas Therapeutics AB (publ), ARS Pharmaceuticals and ANI Pharmaceuticals. Learn More about companies similar to Sage Therapeutics.

How do I contact Sage Therapeutics' investor relations team?

Sage Therapeutics' physical mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 299-8380 and its investor relations email address is [email protected]. The official website for Sage Therapeutics is www.sagerx.com. Learn More about contacing Sage Therapeutics investor relations.